In this issue:
Efficacy of pirtobrutinib in pre-treated CLL and SLL patients
Standard care versus axi-cel
Durability of Ibrutinib plus venetoclax
Underlying CLL-induced immune dysfunction
Imatinib versus ponatinib in ALL patients
PFS rates from ibrutinib + venetoclax for untreated CLL patients
Efficacy of Pola-based therapy in Thailand
Comparing tafasitamab + lenalidomide to other therapies
Final analysis of KEYNOTE-170 study
Simplified CIRS-based comorbidity index
Please login below to download this issue (PDF)